U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07489703) titled 'SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC' on March 18.
Brief Summary: This is a phase II, open-label, single-arm study evaluating the efficacy and safety of SHR-A1811 (a HER2-targeted ADC) combined with AK112 (a PD-1/VEGF bispecific antibody) in patients with HER2-amplified or overexpressed locally advanced or metastatic NSCLC.
Study Start Date: April 30
Study Type: INTERVENTIONAL
Condition:
Non-Small Cell Lung Cancer
Intervention:
DRUG: SHR-A1811 plus AK112
Patients will receive the combination of SHR-A1811 and AK112 until disease progression or until other predefined discontinuation criteria are met, whi...